Howland Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Howland Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-6,000	Closed	-$323K	–	200
2014 Q3	$323K	Hold	6,000	–	–	0.03%	161
2014 Q2	$315K	Hold	6,000	–	–	0.03%	159
2014 Q1	$317K	Hold	6,000	–	–	0.04%	150
2013 Q4	$240K	Sell	6,000 -1,200	-17%	-$47.3K	0.03%	168
2013 Q3	$272K	Sell	7,200 -6,000	-45%	-$234K	0.04%	150
2013 Q2	$517K	Buy	+13,200	New	+$514K	0.08%	102

Other funds holding TEVA

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

ACM

Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Howland Capital Management's TEVA Position: Q4 2014 in Review

Howland Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2014, closing a stake of 6,000 shares — an estimated $323K sold.

Howland Capital Management first reported a position in TEVA in Q2 2013 and held it in 6 quarters. The position peaked at $517K in Q2 2013. 821 funds tracked by Wall St. Rank hold TEVA as of Q4 2014.

Howland Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
Howland Capital Management sold 6,000 Teva Pharmaceuticals shares in Q4 2014, an estimated $323K.
Howland Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 6 quarters.
Howland Capital Management's Teva Pharmaceuticals position peaked at $517K in Q2 2013.
821 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2014.

Based on Howland Capital Management's 13F filing for Q4 2014, filed 3 Feb 2015.